Offnation Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10525610		
Filing Date		2006-03-24		
First Named Inventor	Willia	Williams		
Art Unit		1643		
Examiner Name	Harris			
Attorney Docket Number		W1107/20010		

				U.S	.PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant			,Columns,Lines wher ant Passages or Rele s Appear	
	1	5770563	В1	1998-06-23	Roberts				
If you wisl	h to a	⊥ dd additional U.S. Pate	nt citatio	ı n information ı	lease click the	Add button.	1	Add	
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document		Releva	,Columns,Lines wher ant Passages or Rele s Appear	
	1								
If you wish	h to a	dd additional U.S. Publ		<u>'</u>	on information		d button	Remove	-
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	y Kind	Publication Applicant of cited Document		e or \	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Т5
71	1								
If you wisl	h to a	dd additional Foreign P	atent Do	cument citatio	n information p	lease click the Add	button	Add	
			NON	I-PATENT LIT	ERATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite <b>N</b> o	Include name of the a (book, magazine, jour publisher, city and/or	nal, seria	al, symposiu <mark>m</mark>	, catalog, etc),				<b>T</b> 5

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10525610	
Filing Date		2006-03-24	
First Named Inventor	Willia	ims	
Art Unit		1643	
Examiner Name	Натія	Harris	
Attorney Docket Number		W1107/20010	

	1	Shafiee A et al., Inhibition of Retinal Angiogenesis by Peptides Derived from Thrombospondin-1. Invest Opthamol Vis Sci. 2000; 41: 2378-2388.						
	2	Hugo CPM et al, Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo. Kidney International. 1999; 55: 2236-2249.						
	3	Taraboletti G et al.; The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. The Faseb Journal. 2000; 14:1674-1676.						
	4	Damas C et al., The 33-kDa Platelet α-granule Membrane Protein (GMP-33) is an N-terminal Proteolytic Fragment of Thromobospondin. Thrombosis and Haemostasis. 2001; 86: 887-893.						
71	5	Kuroi K et al.; Circulating angiogenesis regulators in cancer patients. Int J Biol Markers. 2001; 16: 5-26.						
	6	Morandi V et al.; Characterization of a novel monoclonal antibody (V58A4) raised against a recombinant NH2-terminal heparin-binding fragment of human endothelial cell thrombospondin. FEBS Letters. 1994; 346: 156-160.						
If you wis	sh to a	add additional non-patent literature document citation information please click the Add button Add	_					
		EXAMINER SIGNATURE	_					
Examine	r Sign	nature Date Considered	Т					
		Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a	_					

<sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if

English language translation is attached.